Autosomal Recessive Nonsyndromic Hearing Loss 48

1. Disease Information

• Overview: A rare, inherited form of nonsyndromic sensorineural hearing impairment presenting at/before birth, caused by dysfunction of the cochlear hair‑cell mechanotransduction apparatus. It is isolated (nonsyndromic) — hearing loss is the only clinical feature.
• Key identifiers:
• OMIM (phenotype): #609439 — "Deafness, autosomal recessive 48 (DFNB48)"
• Gene: CIB2, OMIM *605564; HGNC:24579; NCBI Gene: 10518; Ensembl: ENSG00000136010; UniProt: O75838; locus 15q25.1
• MONDO: maps to OMIM:609439 (autosomal recessive nonsyndromic hearing loss 48)
• ICD‑11: AB52 (sensorineural hearing loss) / hereditary hearing impairment; ICD‑10: H90.3–H90.5 (no DFNB48‑specific code)
• MeSH: "Hearing Loss, Sensorineural"; "Deafness"
• Orphanet: within "Rare genetic deafness / autosomal recessive nonsyndromic sensorineural deafness type DFNB"
• Synonyms: DFNB48; Deafness, autosomal recessive 48; CIB2‑related nonsyndromic hearing loss.
• Information source: Aggregated disease‑level resources (OMIM/Orphanet) plus individual patient/consanguineous‑pedigree studies (predominantly Pakistani, plus Iranian, Turkish, Dutch families). Evidence type: human clinical + model organism + in vitro.

Primary citations: PMID 23023331 (Riazuddin 2012, discovery); PMID 29112224 (Booth 2018, NSHL vs USH).

2. Etiology

• Primary cause — genetic: Biallelic pathogenic variants in CIB2 (necessary and sufficient). Loss‑of‑function (nonsense, frameshift, splice) and specific missense variants cause disease via loss of function; heterozygous carriers are unaffected (PMID 29112224, 23023331).
• Genetic risk factors: The CIB2 genotype itself; consanguinity / autozygosity (94.4% of affected individuals in Pakistani cohorts are homozygous; PMID 30303587); founder ancestry carrying c.272T>C p.(Phe91Ser).
• Environmental risk factors: None established. DFNB48 is not caused by toxins, noise, occupational exposure, radiation, diet, or lifestyle. General ototoxins (aminoglycosides) and noise are not specifically linked to CIB2 (contrast MT‑RNR1 m.1555A>G). Sex: no predilection (autosomal). Family history/consanguinity are the operative demographic risks.
• Protective factors: No human protective alleles identified. Biologically, the paralog CIB3 provides intrinsic redundancy in the vestibule and retina (limiting the phenotype to hearing) but does not protect the cochlea (PMID 34089643).
• Gene–environment interactions: None documented specifically for CIB2.
• Epigenetic / chromosomal mechanisms: None known; no recurrent CNV/structural or methylation mechanism reported.

3. Phenotypes

Core phenotype (100% of affected): bilateral sensorineural hearing loss.

• Onset: neonatal/congenital or prelingual.
• Severity: typically severe‑to‑profound; variable — deafness with c.272T>C in one Pakistani family was "remarkably less severe" than in other families with the same allele, indicating variable expressivity/modifiers (PMID 26173970).
• Progression: generally stable/non‑progressive; chronic, lifelong.
• Frequency among affected: hearing loss ~100%; notably ABSENT are retinitis pigmentosa (HP:0000510) and vestibular dysfunction — their absence defines the nonsyndromic status vs USH1J.
• Quality‑of‑life impact: primary burden is on spoken‑language acquisition, communication, education, and psychosocial development; largely mitigated by early amplification/cochlear implantation. No pain, no systemic morbidity.

Citations: PMID 29112224, 26173970, 29086887.

4. Genetic / Molecular Information

• Causal gene: CIB2 — calcium‑ and integrin‑binding family member 2 (HGNC:24579; OMIM *605564; NCBI 10518; UniProt O75838). Encodes a small (~187 aa) EF‑hand protein with calcium‑binding domains.
• Pathogenic variants (representative):
• c.272T>C, p.(Phe91Ser) — recurrent founder missense, prevalent DFNB48 cause in Pakistan (PMID 23023331, 29086887).
• c.196C>T p.(Arg66Trp), c.97C>T, c.556C>T and other missense (PMID 26173970).
• Nonsense/LOF: e.g., p.(Gln12), p.(Tyr110) (PMID 29084757); frameshift and additional LOF alleles (PMID 29112224).
• Variant classification: Pathogenic / likely pathogenic per ACMG/AMP (ClinVar). Biallelic LOF → ARNSHL (not USH) (PMID 29112224).
• Variant types: missense, nonsense, frameshift, splice‑site (predominantly missense and LOF); no recurrent structural/CNV mechanism.
• Allele frequency: individual pathogenic alleles are rare in gnomAD; founder alleles enriched in South‑Asian subpopulations.
• Origin: germline (constitutional); not somatic.
• Functional consequence: loss of function — disrupted CIB2–TMC1/TMC2 interaction and impaired stereocilia organization; missense alleles are proposed to alter integrin binding and channel modulation while preserving localization/calcium buffering in some cases (PMID 26173970).
• Modifier genes: CIB3 (paralog, functional redundancy); WHRN (genetic interaction in mice; PMID 40083274). Other MET‑complex genes (TMC1/2, LHFPL5, TMIE, LOXHD1) are functional partners.
• Epigenetics / chromosomal abnormalities: none established.

5. Environmental Information

Not applicable — DFNB48 is a purely genetic, monogenic disorder. No environmental toxin, radiation/pollution, occupational exposure, lifestyle factor (smoking/diet/alcohol/exercise), or infectious agent causes or triggers it. (Acquired congenital SNHL from e.g. congenital CMV/TORCH is a differential diagnosis, not a cause of DFNB48.)

6. Mechanism / Pathophysiology

Ordered causal chain (initiating lesion → clinical manifestation)

1. Biallelic pathogenic CIB2 variant → loss of functional CIB2 protein (or a CIB2 that cannot bind its partners). [demonstrated]
2. Loss of CIB2 → disrupted CIB2–TMC1/TMC2 interaction at the tips of shorter‑row stereocilia → the MET channel complex fails to operate, even though tip links remain intact. [demonstrated — PMID 28663585]
3. In parallel branch: loss of CIB2 → loss of CIB2–WHRN‑dependent organization of the stereocilia staircase → abnormal stereocilia bundle morphology / overgrowth of shorter transducing‑row stereocilia. [demonstrated — PMID 28663585, 40083274]
4. Non‑functional MET → failure to convert sound‑induced mechanical deflection into receptor (transduction) current → loss of hair‑cell depolarization/signaling. [demonstrated — abolished MET in mice]
5. Loss of transduction + CIB2's role in survival → hair‑cell dysfunction and progressive hair‑cell degeneration in the organ of Corti. [demonstrated/inferred — PMID 29084757]
6. Cochlear sensory failure → no afferent auditory signal to the cochlear nerve/CNS → congenital sensorineural hearing loss. [demonstrated]
7. Branch (spared organs): In vestibule and retina, the paralog CIB3 (and CIB1) substitutes → balance and vision preserved → phenotype remains nonsyndromic. [demonstrated — PMID 34089643]

Detail by category

• Molecular pathway / biochemical defect: hair‑cell mechanotransduction (an ion‑channel/receptor‑complex defect, not a classical signaling cascade). CIB2 is a Ca²⁺‑binding auxiliary subunit of the TMC1/TMC2 pore complex (with TMIE, LHFPL5, PCDH15). EF‑hand calcium binding modulates the complex.
• Protein dysfunction: loss of function; disrupted protein–protein interactions (TMC1/2, WHRN). Missense variants may impair integrin/partner binding.
• Cellular processes: impaired sensory transduction; hair‑cell degeneration/death; dysregulated stereocilia actin cytoskeleton/bundle morphogenesis.
• Metabolic / immune / inflammatory: not implicated.
• Tissue damage mechanism: sensory hair‑cell loss (not fibrosis/ischemia/autoimmune).
• GO terms: sensory perception of sound (GO:0007605); inner ear receptor cell development (GO:0060113); regulation of stereocilium/microvillus length; calcium ion binding (GO:0005509). Cellular component: stereocilium (GO:0032420), stereocilium tip (GO:0032426), stereocilium bundle (GO:0032421).
• Cell types (CL): cochlear inner hair cell (CL:0000589), cochlear outer hair cell (CL:0000601), auditory hair cell (CL:0000202).

Citations: PMID 28663585, 29255404, 40083274, 34089643, 29084757, 23023331.

7. Anatomical Structures Affected

• Organ level (primary): cochlea (UBERON:0001844), specifically the organ of Corti / spiral organ (UBERON:0002227) within the inner ear (UBERON:0001846). Body system: nervous/sensory (auditory).
• Secondary involvement: none directly; downstream central auditory pathway deprivation affects language cortex development if untreated.
• Tissue/cell level: auditory sensory epithelium (neuroepithelium); affected cells = cochlear inner and outer hair cells (CL:0000589 / CL:0000601). Vestibular hair cells and retinal photoreceptors are spared in humans.
• Subcellular level: the stereocilia and their tips (mechanotransduction apparatus); GO:0032420 stereocilium, GO:0032426 stereocilium tip; plasma membrane; EF‑hand Ca²⁺‑binding protein.
• Localization / lateralization: bilateral, symmetric (HP:0008619).

Citations: PMID 23023331 (stereocilia localization); 28663585.

8. Temporal Development

• Onset: congenital / prelingual; onset pattern is chronic (present from birth), not acute or episodic.
• Progression: generally stable / non‑progressive; variable severity across genotypes/families. Disease duration is lifelong (chronic).
• Course pattern: persistent; no relapsing‑remitting or fluctuating course; no spontaneous remission.
• Critical period: early childhood auditory neuroplasticity window — early diagnosis and habilitation (EHDI 1‑3‑6 benchmark: screen ≤1 mo, diagnose ≤3 mo, intervene ≤6 mo) determine language outcomes; preclinical data show a developmental window for gene‑therapy rescue (PMID 42427029).

9. Inheritance and Population

• Inheritance: autosomal recessive (biallelic). Recurrence risk 25% per pregnancy for carrier couples.
• Penetrance: complete for biallelic pathogenic genotypes. Expressivity: variable (severity differs even for identical alleles; PMID 26173970).
• Anticipation / mosaicism: not applicable / not reported.
• Founder effects: c.272T>C p.(Phe91Ser) is a prevalent Pakistani founder allele (PMID 23023331, 29086887).
• Consanguinity: major driver (homozygosity by descent; PMID 30303587).
• Carrier frequency: rare in outbred populations; elevated in specific consanguineous kindreds; individual alleles rare in gnomAD.
• Epidemiology: Overall congenital SNHL prevalence ≈ 1–3 per 1,000 newborns; DFNB48 is a small fraction of this globally but is one of the more common ARNSHL genes in Pakistan — 4th most common after SLC26A4, MYO7A, GJB2 (PMID 30303587), and among 13 genes accounting for >50% of profound HL in Pakistan (PMID 38534090). No precise DFNB48 prevalence/incidence figure is established (rare disease).
• Demographics: enriched in South Asian (Pakistani/Iranian), Turkish, and some European (Dutch) kindreds; no sex bias; affected from birth (pediatric age distribution at diagnosis).

10. Diagnostics

• Audiological (clinical) tests:
• Screening: Universal Newborn Hearing Screening — otoacoustic emissions (OAE) + automated ABR (AABR/BERA) (PMID 42181374).
• Confirmatory: diagnostic ABR, pure‑tone/behavioral audiometry, tympanometry (to exclude conductive loss). LOINC‑coded audiometry/OAE/ABR panels.
• Imaging: temporal‑bone CT/MRI to exclude structural inner‑ear malformations (usually normal in DFNB48).
• Laboratory biomarkers: none — no blood/urine/enzyme/metabolic biomarker; diagnosis is audiological + molecular.
• Genetic testing (definitive):
• NGS gene panels / whole‑exome sequencing targeting 150–250+ deafness genes (including CIB2): diagnostic yield ~21–48% for congenital SNHL (PMID 38224868 [48%], 29986705 [42%], 35580552 [21%]).
• Single‑gene / targeted testing appropriate in founder populations (e.g., tetra‑primer ARMS for p.Phe91Ser; PMID 29086887).
• WGS for panel/exome‑negative cases; CMA/karyotype/FISH/mtDNA/repeat testing are not indicated for isolated CIB2 deafness.
• Variant interpretation per ACMG/AMP (ClinVar/ClinGen).
• Clinical criteria / differential diagnosis: bilateral nonsyndromic SNHL with normal vision and balance. Rule out: other ARNSHL (GJB2/DFNB1, SLC26A4/Pendred, MYO15A, TMC1, OTOF/DFNB9); Usher syndrome (USH1J) — assess vision/vestibular function; acquired causes (congenital CMV/TORCH).
• Screening (asymptomatic): newborn hearing screening; carrier screening and cascade testing of relatives.

11. Outcome / Prognosis

• Survival/mortality: not life‑limiting; normal life expectancy; no disease‑specific mortality.
• Morbidity/disability: communication and language disability; downstream educational and psychosocial impacts if unaddressed. ICF domains: hearing functions, communication, social participation.
• Quality‑of‑life tools: generic (EQ‑5D, PROMIS) and hearing‑specific instruments; outcomes strongly modifiable by intervention.
• Disease course/complications: stable auditory deficit; main "complication" is speech‑language delay without early habilitation.
• Recovery potential: none spontaneously; substantial functional recovery of hearing/oral language with cochlear implantation, especially when performed early.
• Prognostic factors: age at intervention (earlier = better), rehabilitation intensity/appointment adherence, neurodevelopmental comorbidities, and cochlear/cochlear‑nerve integrity on imaging (PMID 42330611, 41895171). No molecular prognostic biomarker beyond genotype–severity trends.

12. Treatment

• Pharmacotherapy: None corrects the MET defect (no approved drug; no pharmacogenomic modifier). NCIT: n/a.
• Rehabilitative / device (standard of care):
• Hearing aids (residual hearing) — NCIT: Hearing Aid.
• Cochlear implantation for severe‑to‑profound loss — NCIT: Cochlear Implant; paired with auditory‑verbal / speech‑language therapy (NCIT: Speech Therapy). Language outcomes depend on early implantation and rehabilitation (PMID 42330611, 41895171).
• Advanced/experimental — gene therapy:
• Preclinical (CIB2‑specific): single semicircular‑canal AAV‑Cib2 (and AAV‑Cib3) injection restored stereocilia architecture and hearing in Cib2‑mutant mice within a critical window (PMID 42427029). NCIT: Gene Therapy; AAV Vector.
• Clinical precedent (analogous gene): AAV cochlear gene therapy for biallelic OTOF/DFNB9 — FDA‑approved Otarmeni (2026); ~75% of early‑trial children met the primary hearing endpoint at 24 weeks (PMID 42470357); ≥5 DFNB9 trials ongoing (PMID 41812306). Establishes feasibility; CIB2 gene therapy remains preclinical.
• Surgical: cochlear implant surgery (transmastoid/round‑window).
• Treatment strategy: etiology‑guided, early habilitation; emerging "restore when biology permits, bypass when it does not" hierarchy (PMID 42470357). Personalized medicine: genotype‑directed eligibility for future gene therapy.

13. Prevention

• Primary prevention: no lifestyle/vaccine route (monogenic). Risk reduction is genetic: preconception genetic counseling, expanded carrier screening, and reproductive options — prenatal diagnosis and preimplantation genetic testing (PGT‑M) for known familial variants; counseling on consanguinity risk. NCIT: Genetic Counseling; Carrier Screening; Prenatal Diagnosis; Preimplantation Genetic Testing.
• Secondary prevention: universal newborn hearing screening → early diagnosis → early habilitation (EHDI 1‑3‑6).
• Tertiary prevention: cochlear implantation + intensive (re)habilitation to prevent language/developmental morbidity; educational support.
• Cascade screening: test at‑risk relatives once a familial genotype is known.
• Public health: deafness gene carrier‑screening programs (already impactful for GJB2 in some populations); consanguinity education in high‑risk communities.

14. Other Species / Natural Disease

• Taxonomy / orthologs: CIB2 is evolutionarily conserved. Orthologs: mouse Cib2 (NCBI Gene 208768; NCBI Taxon 10090), zebrafish cib2 (Taxon 7955), Drosophila melanogaster ortholog (Taxon 7227) — all required for hair‑cell/mechanosensory function (PMID 23023331).
• Natural disease / veterinary: No spontaneous naturally occurring CIB2 deafness is catalogued in OMIA as a recognized companion‑animal/wildlife disease; disease models are engineered. (Not applicable / none reported.)
• Comparative pathology: mouse and zebrafish reproduce hair‑cell mechanotransduction failure; conservation of the MET‑complex mechanism across vertebrates and invertebrates supports deep evolutionary conservation of CIB2 function.
• Transmission: not applicable (non‑infectious, non‑zoonotic).

15. Model Organisms

• Mouse (Mus musculus, primary model):
• Cib2‑knockout and human deafness knock‑in lines: deaf, no cochlear MET, stereocilia bundle defects/overgrowth (PMID 28663585, 29255404).
• Genetic‑interaction model: Cib2;Whrn double mutants (PMID 40083274).
• Recapitulation: faithfully models profound congenital deafness and MET loss. Limitation / species difference: mice show vestibular dysfunction (vestibular CIB3 compensation differs from human) and no retinal degeneration, so mice do not fully mirror the human "hearing‑only, balance‑normal" phenotype.
• Resources: MGI, IMPC.
• Zebrafish (Danio rerio): cib2 required for hair‑cell function/development (PMID 23023331); resource: ZFIN.
• Drosophila melanogaster: CIB2 ortholog essential for hair‑cell/mechanosensory development (PMID 23023331); resource: FlyBase.
• In vitro / cellular: heterologous expression (COS‑7) for calcium‑response and localization assays (PMID 26173970); AlphaFold2‑multimer structural modeling of CIB2–WHRN (PMID 40083274).
• Applications: dissecting MET‑complex assembly, stereocilia morphogenesis, genotype–function relationships, and AAV gene‑therapy proof‑of‑concept (PMID 42427029).

Supported vs Refuted Hypotheses

Supported - CIB2 biallelic variants cause DFNB48 via loss of hair‑cell MET (PMID 28663585, 29255404). - Biallelic LOF causes nonsyndromic deafness, not Usher syndrome (PMID 29112224). - CIB2 has an independent WHRN‑dependent role in stereocilia architecture (PMID 40083274). - CIB3 redundancy explains sparing of vestibule/retina (PMID 34089643). - AAV gene therapy can rescue the cochlear phenotype in models (PMID 42427029); clinically validated for the analogous OTOF deafness (PMID 42470357).

Refuted / revised - The original proposal that CIB2 causes Usher syndrome type 1J is refuted for biallelic LOF genotypes (PMID 29112224); CIB2 has been "disqualified as an USH‑causing gene."

Limitations and Future Directions

• Limitations: No large natural‑history registry or precise DFNB48 prevalence; genotype–phenotype (severity) correlations are incompletely explained (modifiers such as CIB3 dosage remain hypothetical); most mechanistic evidence is from mouse/zebrafish, which imperfectly mirror the human sensory‑organ‑specificity; no human‑specific molecular biomarker.
• Future directions: (1) CIB2‑targeted AAV gene therapy toward first‑in‑human trials; (2) high‑resolution structures of the CIB2–TMC1 MET complex to guide variant interpretation and therapy; (3) systematic ACMG re‑classification of CIB2 VUS with functional assays; (4) modifier‑gene (CIB3/WHRN) studies to explain variable expressivity; (5) equitable carrier‑screening and counseling in high‑consanguinity populations.

Key References (PMID)

23023331 · 29112224 · 28663585 · 29255404 · 29084757 · 40083274 · 34089643 · 42427029 · 30303587 · 29086887 · 26173970 · 38534090 · 38224868 · 29986705 · 35580552 · 42181374 · 42470357 · 41812306 · 42330611 · 41895171

Artifacts

• OpenScientist final report
• OpenScientist final report

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

• HP:0008619 (2 mentions) - the report calls it "Bilateral SNHL", "bilateral, symmetric", "Localization / lateralization: bilateral, symmetric"; HP calls it Bilateral sensorineural hearing impairment

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

• HP:0011476 (1 mention) - the report calls it "Profound SNHL"; HP calls it Profound sensorineural hearing impairment, and lists "Profound sensorineural hearing loss" among its other names
• HP:0008625 (1 mention) - the report calls it "Severe SNHL"; HP calls it Severe sensorineural hearing impairment, and lists "Severe sensorineural deafness" among its other names
• GO:0007605 (1 mention) - the report calls it "GO terms: sensory perception of sound"; GO calls it sensory perception of sound**
• UBERON:0002227 (1 mention) - the report calls it "organ of Corti / spiral organ"; UBERON calls it spiral organ of cochlea, and lists "spiral organ of Corti" among its other names
• UBERON:0001846 (1 mention) - the report calls it "inner ear"; UBERON calls it internal ear, and lists "inner ear" among its other names

Terms named inconsistently

The report gives these identifiers more than one name of its own:

• HP:0008619 - called "Bilateral SNHL", "bilateral, symmetric", "Localization / lateralization: bilateral, symmetric"

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: OMIM.